Effects of bucindolol in heart failure

The American Journal of Cardiology

Volumn 71, Issue 9, 1993, Pages

  Eichhorn, Eric J ^a,b  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUCINDOLOL; NORADRENALIN; RENIN;

BETA ADRENERGIC RECEPTOR BLOCKING; CONGESTIVE HEART FAILURE; DRUG TOLERANCE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE; HEART STROKE VOLUME; HUMAN; LUNG ARTERY PRESSURE; NORADRENALIN BLOOD LEVEL; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANIMAL; HEART FAILURE, CONGESTIVE; HEMODYNAMICS; HUMAN; PROPANOLAMINES;

EID: 0027506343     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9149(93)90089-U     Document Type: Article

References (67)

1. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure
2. Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope
3. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure
4. Xamoterol in severe heart failure
5. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure
6. Effect of milrinone on mortality in severe chronic heart failure. The prospective randomized milrinone survival evaluation (PROMISE)
7. Is activation of the sympathetic nervous system beneficial or detrimental to the patient with chronic heart failure? Lessons learned from clinical trials with β-adrenergic agonists and antagonists
8. Captopril in congestive heart failure: improved left ventricular function with decreased metabolic cost
9. A cooperative multicenter study of captopril in congestive heart failure Hemodynamic effects and longterm response
10. Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study
11. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy
12. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial
13. Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy
14. Long-term β-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol
15. Chronic β-blocker-vasodilator therapy improved cardiac function in idiopathic dilated cardiomyopathy: a double blind, randomized study of bucindolol versus placebo
16. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure: Improvements in hemodynamic, contractile, and diastolic performance with bucindolol
17. Usefulness of bucindolol in congestive heart failure
18. Dose response of beta blocker therapy in heart failure: a multicenter, randomized trial of bucindolol versus placebo
19. β-blockade with bucindolol in heart failure due to ischemic vs idiopathic dilated cardiomyopathy
20. Long-term (2 year) beneficial effects of beta-adrenergic blockade with bucindolol in patients with idiopathic dilated cardiomyopathy
21. Effects of enalapril on mortality in severe congestive heart failure results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
22. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure
23. Prolongation of survival in congestive cardiomyopathy by beta receptor blockade
24. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy
25. The paradox of β-adrenergic blockade for the management of congestive heart failure
26. Mechanism of action of bucindolol in human ventricular myocardium
27. Cardiovascular drugs
28. β-Adrenoceptor and cardiovascular effects of MJ 13105 (bucindolol) in anesthetized dogs and rats
29. Studies on the vasodilator actions of bucindolol in the rat
30. Pharmacology of bucindolol in isolated canine vascular smooth muscle
31. In vitro effects of beta adrenoceptor agonists and antagonists on the rat ovarian suspensory ligament
32. Hemodynamic properties of bucindolol, a beta-adrenoceptor blocking drug with vasodilator activity
33. Comparative β-adrenoceptor blocking effect and pharmacokinetics of bucindolol and propranolol in man
34. The pharmacokinetics of bucindolol and its major metabolite in essential hypertension
35. Comparison of the haemodynamic effects of bucindolol, propranolol, and pindolol in healthy volunteers
36. Bucindolol, a beta-adrenoceptor blocker with vasodilatory action: its effect in systemic hypertension
37. Selectivity of the intrinsic sympathomimetic activity of the β-adrenergic blocking drug bucindolol
38. Receptor pharmacology of carvedilol in the human heart
39. Affinity of bucindolol to α- and β- adrenoceptor subtypes as evaluated by radio-ligand binding studies
40. Bucindolol has serotonin and α-adrenoceptor blocking properties
41. Beneficial effects of bucindolol in a canine model of pentobarbital-induced heart failure
42. The pharmacokinetics of bucindolol
43. Effect of bucindolol on the airway function in asthmatics
44. Beta-blocker bucindolol: A potent systemic and coronary vaodilator in patients with coronary artery disease
45. Cardioprotective action of selected β-blockers in rats
46. Bucindolol, a new beta-antagonist effective against ventricular fibrillation (VF) associated with myocardial ischemia in pigs
47. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy
48. Comparison of captopril and enalapril in patients with severe chronic heart failure
49. Differences in β-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy
50. Myocardial fibrosis and pathologic hypertrophy in the rat with renovascular hypertension
51. Myocardial metabolic and hemodynamic effects of dichloroacetate in coronary artery disease
52. Improved hemodynamic function in congestive heart failure with the metabolic agent sodium dichloroacetate (DCA)
53. Effects of bucindolol on neurohormonal activation in congestive heart failure
54. Exercise testing and training with β-adrenergic blockade: role of the drug washout period in “unmasking” a training effect
55. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
56. Angiotensins and the failing heart. Enhanced positive inotropic response to angiotensin I in cardiomyopathic hamster heart in the presence of captopril
57. Value of carvedilol in congestive heart failure secondary to coronary artery disease
58. 1-adrenergic receptor partial agonist xamoterol on left ventricular diastolic function. An evaluation after 1–6 years of oral therapy
59. Review of clinical experience with xamoterol. Effects on exercise capacity and symptoms in heart failure
60. Double-blind placebocontrolled comparison of digoxin and xamoterol in chronic heart failure
61. Improvement of global and regional left ventricular function in patients with previous myocardial infarction by a new β1 adrenoceptor partial agonist, ICI 118,587
62. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness
63. Beta blockade during and after myocardial infarction: an overview of the randomized trials
64. Potential deleterious effects of inotropic agents in the therapy of chronic heart failure
65. Ventricular antiarrhythmic effects of beta adrenergic blocking drugs: a review of mechanism and clinical studies
66. Prophylaxis of ventricular fibrillation after acute experimental coronary occlusion by chronic beta adrenergic blockade with atenolol